Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 2/2013

01-04-2013 | Short Research Report

Utilization of fluconazole in an intensive care unit at a university hospital in Brazil

Authors: Tânia Pereira Salci, Marina Gimenes, Carlos Aparecido dos Santos, Terezinha Inez Estivalet Svidzinski, Silvana Martins Caparroz-Assef

Published in: International Journal of Clinical Pharmacy | Issue 2/2013

Login to get access

Abstract

Background Fungi have been developing resistance and merit greater attention because these microorganisms are among the major causes of hospital infection. Objective The aim of the present study was to characterize the pattern of fluconazole use in an adult intensive care unit. Setting The setting was an intensive care unit at a university hospital in Brazil. Method An observational retrospective study was performed between 2007 and 2010. The use of antifungal drugs was calculated as the defined daily dose per 1,000 patient-days. The pattern of fluconazole use was determined by analyzing patient charts. Results Fluconazole accounted an average of 66.6 % of the antifungal agents prescribed. All of the patients exhibited important risk factors for the development of fungal infection. Treatment was empirical in 45.2 % of the cases and therapeutic in 54.8 % of the cases. The dose interval was inadequate in 51.1 % of the treatments. Fluconazole at doses ≥400 mg/day was related to a greater likelihood of survival. C. albicans was the most prevalent species (31.3 %). Urine was the biological material with the greatest number of positive mycological exams (71.9 %). Conclusion This study found a high utilization of fluconazole and, in most cases, its administration at intervals that were different from the recommended intervals.
Literature
1.
go back to reference Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–9.PubMedCrossRef Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–9.PubMedCrossRef
2.
go back to reference Yap HY, Kwok KM, Gomersall CD, Fung SC, Lam TC, Leung PN, et al. Epidemiology and outcome of Candida bloodstream infection in an intensive care unit in Hong Kong. Hong Kong Med J. 2009;15(4):255–61.PubMed Yap HY, Kwok KM, Gomersall CD, Fung SC, Lam TC, Leung PN, et al. Epidemiology and outcome of Candida bloodstream infection in an intensive care unit in Hong Kong. Hong Kong Med J. 2009;15(4):255–61.PubMed
3.
go back to reference Swoboda S, Lichtenstern C, Ober MC, Taylor LA, Störzinger D, Michel A, et al. Implementation of practice guidelines for antifungal therapy in a surgical intensive care unit and its impact on use and costs. Chemotherapy. 2009;55(6):418–24.PubMedCrossRef Swoboda S, Lichtenstern C, Ober MC, Taylor LA, Störzinger D, Michel A, et al. Implementation of practice guidelines for antifungal therapy in a surgical intensive care unit and its impact on use and costs. Chemotherapy. 2009;55(6):418–24.PubMedCrossRef
4.
go back to reference Natsch S, Steeghs MH, Hekster YA, Meis JF, van der Meer JW, Kullberg BJ. Use of fluconazole in daily practice: still room for improvement. J Antimicrob Chemother. 2001;48(2):303–10.PubMedCrossRef Natsch S, Steeghs MH, Hekster YA, Meis JF, van der Meer JW, Kullberg BJ. Use of fluconazole in daily practice: still room for improvement. J Antimicrob Chemother. 2001;48(2):303–10.PubMedCrossRef
5.
go back to reference Lam SW, Eschenauer GA, Carver PL. Evolving role of early antifungals in the adult intensive care unit. Crit Care Med. 2009;37(5):1580–93.PubMedCrossRef Lam SW, Eschenauer GA, Carver PL. Evolving role of early antifungals in the adult intensive care unit. Crit Care Med. 2009;37(5):1580–93.PubMedCrossRef
6.
go back to reference De Bellis P, Bonfiglio M, Gerbi G, Bacigalupo P, Buscaglia G, Guido P, et al. High-dose fluconazole therapy in intensive care unit. Minerva Anestesiol. 2003;69(3):145–52.PubMed De Bellis P, Bonfiglio M, Gerbi G, Bacigalupo P, Buscaglia G, Guido P, et al. High-dose fluconazole therapy in intensive care unit. Minerva Anestesiol. 2003;69(3):145–52.PubMed
7.
go back to reference Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009;48(5):503–35.PubMedCrossRef Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009;48(5):503–35.PubMedCrossRef
8.
go back to reference Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006;6:21.PubMedCrossRef Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006;6:21.PubMedCrossRef
9.
go back to reference Smith CJ. Analysing censored data using Kaplan-Meier methods; survival analysis. Phlebology. 2011;26(4):173–4.PubMedCrossRef Smith CJ. Analysing censored data using Kaplan-Meier methods; survival analysis. Phlebology. 2011;26(4):173–4.PubMedCrossRef
Metadata
Title
Utilization of fluconazole in an intensive care unit at a university hospital in Brazil
Authors
Tânia Pereira Salci
Marina Gimenes
Carlos Aparecido dos Santos
Terezinha Inez Estivalet Svidzinski
Silvana Martins Caparroz-Assef
Publication date
01-04-2013
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 2/2013
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-012-9726-z

Other articles of this Issue 2/2013

International Journal of Clinical Pharmacy 2/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.